On the other hand, the HGF/MET axis promotes the invasive growth of cancers; therefore, evaluation of HGF/MET targeted therapy is performed for hepatocellular carcinoma and cholangiocarcinoma (CCA) [17,18,19]. This evidence concerns the gene MET and hepatocellular carcinoma.